Related Experiment Videos
Silent cardiac ischemia
1Department of Cardiology, University of Florida College of Medicine, Gainesville, 32610, USA. CONTICR@medicine.ufl.edu
Insights
Treating asymptomatic patients with silent cardiac ischemia requires careful consideration of intervention risks versus benefits. The Asymptomatic Cardiac Ischemia Pilot (ACIP) Study offers insights into managing this "murky middle" group to prevent future cardiac events.
Area of Science:
- Cardiology
- Preventative Cardiovascular Medicine
- Clinical Trial Research
Background:
- A significant patient group exists with documented cardiac ischemia but no symptoms, posing treatment dilemmas.
- The management of these asymptomatic patients, often termed the "murky middle," presents unique clinical challenges.
- Defining the threshold for intervention based solely on test abnormalities is complex.
Purpose of the Study:
- To explore the critical questions surrounding the treatment of patients with silent cardiac ischemia.
- To evaluate the potential benefits and risks of intervening in asymptomatic individuals with documented ischemia.
- To establish criteria for justifying interventions and measuring their efficacy in preventing future cardiac events.
Main Methods:
- The article discusses insights derived from the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study.
- Focuses on the decision-making process for treating silent ischemia.
- Examines the justification of risks, costs, and inconvenience of interventions.
Main Results:
- Intervention in asymptomatic patients is justifiable only if it demonstrably prevents future cardiac events.
- The ACIP Study provides valuable data on the outcomes of managing silent ischemia.
- Highlights the need for robust methods to measure intervention efficacy.
Conclusions:
- The management of silent cardiac ischemia serves as a crucial model for other preventative cardiovascular strategies.
- Further research is needed to refine treatment guidelines for asymptomatic patients with ischemic heart disease.
- Emphasizes a risk-benefit analysis for all interventions in this patient population.
Abstract:
Between the extremes of those who have no coronary disease and those limited by it are those with documented ischemia but no symptoms. Treating these patients in the "murky middle" generates some important questions. Should we treat patients with no symptoms solely on the basis of test abnormalities? Can we make the asymptomatic person better? What interventions would we use to treat such a disorder? How do we justify the risk, inconvenience, and cost of these interventions? How do we measure the efficacy of our intervention? Treating the asymptomatic person can only be justified if we prevent future events through our intervention. The management of silent ischemia can serve as a model for handling other preventative measures. The following article describes the issues around silent cardiac ischemia and some of the insights obtained in the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study.